Literature DB >> 29788889

Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy.

Yunli Shi1, Shengnan Liu2, Shabir Ahmad1, Qingzhi Gao1,2,3.   

Abstract

Increased glycolysis has been one of the metabolic characteristics known as the Warburg effect. The functional and therapeutic importance of the Warburg effect in targeted therapy is scientifically recognized and the glucose metabolic pathway has become a desirable target of anticancer strategies. Glucose transporters (GLUTs) play an important role in cancer glycolysis to sustain cancer cell proliferation, metastasis and survival. Utilizing the knowledge of differential expression and biological functions of GLUTs offers us the possibility of designing and delivering chemotherapeutics toward targeted tumor tissues for improved cancer selectivity. Inhibition of glucose uptake or glycolysis may effectively kill hypoxic cancer cells. Facilitative drug uptake via active transportation provides the potential opportunity to circumvent the drug resistance in chemotherapy. GLUTs as the hallmarks and biotargets of cancer metabolism enable the design and development of novel targeted theranostic agents. In this updated review, we examine the current scenario of the GLUTs as strategic targets in cancer and the unique concepts for discovery and development of GLUTs-targeted anticancer agents. We highlight the recent progresses on structural biology and underlying mechanism studies of GLUTs, with a brief introduction to the computational approaches in GLUT-mediated drug transport and tumor targeting. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Drug design; Glucose transporters; Medicinal chemistry; Structural biology; Targeted therapy; Transport mechanism; Warburg effect.

Mesh:

Substances:

Year:  2018        PMID: 29788889     DOI: 10.2174/1568026618666180523105234

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  10 in total

1.  Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells.

Authors:  Lichao Guo; Wen Zhang; Yanqi Xie; Xi Chen; Emma E Olmstead; Mengqiang Lian; Baochen Zhang; Yekaterina Y Zaytseva; B Mark Evers; H Peter Spielmann; Xifu Liu; David S Watt; Chunming Liu
Journal:  Mol Cancer Ther       Date:  2022-05-04       Impact factor: 6.009

Review 2.  Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer.

Authors:  Kalpana Tilekar; Neha Upadhyay; Cristina V Iancu; Vadim Pokrovsky; Jun-Yong Choe; C S Ramaa
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-10-21       Impact factor: 10.680

3.  Colon cancer-associated transcript-1 enhances glucose metabolism and colon cancer cell activity in a high-glucose environment in vitro and in vivo.

Authors:  Ge Cui; Yuxuan Huang; Wenming Feng; Yunliang Yao; Hongchang Zhou; Xining Li; Hui Gong; Jun Liu; Yifan Luo; Yandi Sun; Mengya Zhang; Yan Luo; Ting Zhang
Journal:  J Gastrointest Oncol       Date:  2020-12

4.  Glucose Metabolic Reprogramming and Cell Proliferation Arrest in Colorectal Micropapillary Carcinoma.

Authors:  Monika Vyas; Natalie Patel; Romulo Celli; Narendra Wajapeyee; Dhanpat Jain; Xuchen Zhang
Journal:  Gastroenterology Res       Date:  2019-06-07

Review 5.  Small-Molecule Inhibition of Glucose Transporters GLUT-1-4.

Authors:  Elena S Reckzeh; Herbert Waldmann
Journal:  Chembiochem       Date:  2019-11-08       Impact factor: 3.164

Review 6.  Metabolic Symbiosis in Chemoresistance: Refocusing the Role of Aerobic Glycolysis.

Authors:  Lisi Ma; Xiangyun Zong
Journal:  Front Oncol       Date:  2020-01-24       Impact factor: 6.244

Review 7.  Smart Responsive Nanoformulation for Targeted Delivery of Active Compounds From Traditional Chinese Medicine.

Authors:  Xuejun Jiang; Mei Lin; Jianwen Huang; Mulan Mo; Houhe Liu; Yuan Jiang; Xiaowen Cai; Wingnang Leung; Chuanshan Xu
Journal:  Front Chem       Date:  2020-12-10       Impact factor: 5.221

8.  Downregulation of GLUT3 impairs STYK1/NOK-mediated metabolic reprogramming and proliferation in NIH-3T3 cells.

Authors:  Weiye Shi; Yu Fu; Yingze Wang
Journal:  Oncol Lett       Date:  2021-05-14       Impact factor: 2.967

Review 9.  Glucose transporters: Important regulators of endometrial cancer therapy sensitivity.

Authors:  Xing Zhang; Jia-Jing Lu; Ayitila Abudukeyoumu; Ding-Yu Hou; Jing Dong; Jiang-Nan Wu; Li-Bing Liu; Ming-Qing Li; Feng Xie
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

Review 10.  Relationship between metabolic reprogramming and drug resistance in breast cancer.

Authors:  Linlin Lv; Shilei Yang; Yanna Zhu; Xiaohan Zhai; Shuai Li; Xufeng Tao; Deshi Dong
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.